Search
Vortioxetine
go.drugbank.com/drugs/DB09068ApprovedInvestigationalSome serotonin receptors seem to play a relatively neutral or insignificant role in the regulation of mood, but others, such as 5-HT1A autoreceptors and 5-HT7 receptors, appear to play an oppositional … Vortioxetine is an antidepressant medication indicated for the treatment of major depressive disorder (MDD).
Categories: Antidepressive Agents Indicated for DepressionLasofoxifene
go.drugbank.com/drugs/DB06202ApprovedInvestigationalWithdrawnIt was initially developed as Oporia by Pfizer as a treatment for postmenopausal osteoporosis and vaginal atrophy, in which were both rejected for approval by FDA. … Ligand Pharmaceuticals signed a license agreement with Sermonix Pharmaceuticals for the development and commercialization of oral lasofoxifene in the USA.
Tremelimumab
go.drugbank.com/drugs/DB11771ApprovedInvestigationalCTLA-4 is a cell surface receptor expressed on activated T cells to act as a negative regulator for T cells. … [A253717, A253722] After receiving an EMA Committee for Medicinal Products for Human Use (CHMP) recommendation in December 2022, tremelimumab was approved for combined use with [durvalumab].[L46188]
Products: Imjudo Concentrate for Solution for Intravenous Infusion 20 mg/mLIdecabtagene vicleucel
go.drugbank.com/drugs/DB16665ApprovedInvestigational[A232563] Multiple myeloma is typically treated with an immunomodulatory agent like [lenalidomide],[A232593] a proteasome inhibitor like [bortezomib], or an anti-CD38 monoclonal antibody like [isatuximab … [A232558,A232563,L32858] These therapies involve extracting and genetically manipulating T-cells from a patient to express a CAR for a tumor specific antigen.
Omadacycline
go.drugbank.com/drugs/DB12455ApprovedInvestigationalOmadacycline represents a significant advance over the well-known tetracycline family, and has been shown to be highly effective in animal models at treating increasingly problematic, clinically prevalent … Omadacycline has been used in trials studying the treatment of Bacterial Pneumonia, Bacterial Infections, Community-Acquired Infections, and Skin Structures and Soft Tissue Infections.
Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic UseBirch bark extract
go.drugbank.com/drugs/DB16536ApprovedInvestigational[L42365,L42370] Filsuvez, one of these two formulations, is approved for the treatment of partial thickness wounds in patients with epidermolysis bullosa (EB), a rare group of hereditary disorders of the … [L42390] Filsuvez was subsequently approved for the same indication by the US FDA in December 2023.
Trastuzumab deruxtecan
go.drugbank.com/drugs/DB14962ApprovedInvestigationalTrastuzumab deruxtecan is a HER2-directed antibody attached to a topoisomerase inhibitor that is approved for use in certain types of treatment-resistant HER2-positive cancers. … [A188988] Trastuzumab deruxtecan was developed by Daiichi Sankyo in collaboration with AstraZeneca and was first approved by the FDA in 2019.[L10842]
Products: ENHERTU POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/VIALPomalidomide
go.drugbank.com/drugs/DB08910ApprovedInvestigationalPomalidomide, an analogue of thalidomide, is an immunomodulatory antineoplastic agent. FDA approved on February 8, 2013.
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic IndexPrasugrel
go.drugbank.com/drugs/DB06209ApprovedInvestigationalPrasugrel was developed by Daiichi Sankyo Co. and is currently marketed in the United States and Canada in cooperation with Eli Lilly and Company for acute coronary syndromes planned for percutaneous coronary … Similar to clopidogrel, prasugrel is a prodrug that requires enzymatic transformation in the liver to its active metabolite, R-138727.
Products: PRASUGREL AL 5MG HBR FTA, PRASUGREL AL 10MG HBR FTALinzagolix
go.drugbank.com/drugs/DB17083ApprovedInvestigational[A253667] Linzagolix was approved for use in the European Union in June 2022 for the management of symptoms caused by uterine fibroids.[L43627] … Linzagolix is a non-peptide, selective antagonist of the gonadotropin-releasing hormone (GnRH) receptor.